Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Zymeworks Inc. (ZA8.F) Follow Add holdings 10.80 +1.00 +(10.20%) As of 3:29:01 PM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for ZA8.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: ZA8.F View More All News Press Releases SEC Filings Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 Zymeworks Announces Participation in Upcoming Investor Conferences Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 The past five years for Zymeworks (NASDAQ:ZYME) investors has not been profitable